Amyloid PET could be a useful diagnostic tool for patients with mild cognitive impairment (MCI) or suspected Alzheimer’s, according to a study published this summer in JAMA Neurology, yielding changes in diagnosis, treatment decisions and physician confidence regardless if scan results are positive or negative.